Autophagy activation in breast cancer cells in vitro after the treatment with PI3K/AKT/mTOR inhibitors
| Autor: | D. D. Grigoreva, E. M. Zhidkova, E. S. Lylova, A. D. Enikeev, K. I. Kirsanov, G. A. Belitsky, M. G. Yakubovskaya, E. A. Lesovaya |
|---|---|
| Jazyk: | ruština |
| Rok vydání: | 2022 |
| Předmět: | |
| Zdroj: | Успехи молекулярной онкологии, Vol 9, Iss 4 (2022) |
| Druh dokumentu: | article |
| ISSN: | 2313-805X 2413-3787 |
| DOI: | 10.17650/2313-805X-2022-9-4-61-70 |
| Popis: | Introduction. Current chemotherapy of breast cancer has a wide range of disadvantages, in particular, the development of therapy-related infections and hormonal imbalance. Combination of main cytostatic with glucocorticoids allows to broaden its therapeutic interval and to decrease the total toxicity of the treatment. However, long-term treatment with glucocorticoids leads to the development of severe side effects via activation of multiple molecular mechanisms. Thus, glucocorticoids activate prosurvival mTOR-dependent autophagy. Therefore, the evaluation of PI3K (phosphoinositide 3-kinases) / Akt (protein kinase B) / mTOR (mammalian target of rapamycin) inhibitors as adjuvants for breast cancer therapy is important for optimization of treatment protocol.Aim. Analysis of the effects of PI3K/Akt/mTOR inhibitors, rapamycin, wortmannin and LY-294002 in combination with glucocorticoids in breast cancer cell lines of different subtypes.Materials and methods. We demonstrated the inhibition of PI3K/Akt/mTOR signaling and the autophagy induction after the treatment of breast cancer cells with rapamycin, wortmannin and LY-294002 by Western blotting analysis of Beclin-1, phospho-Beclin-1 (Ser93 and Ser30).Conclusion. PI3K/Akt/mTOR inhibitors in combination with Dexamethasone cooperatively inhibited mTOR signaling and activated autophagy in breast cancer cells in vitro. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|